ASSAY DEVELOPMENT CONSULTING SERVICES FOR NINDS' HEAL PROGRAM

NINDS HEAL 计划的检测开发咨询服务

• 批准号: 10700778
• 负责人: LISA MINOR
• 金额: $ 1.44万
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-30 至 2023-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10700778
• 关键词: Address; Biochemical; Biological Assay; Cells; Chronic; Clinical; Clinical Research; Consult; Consultations; Contractor; Development; Helping to End Addiction Long-term; Individual; Knee Osteoarthritis; Logistics; National Institute of Neurological Disorders and Stroke; Opiate Addiction; Pain; Pain management; Perioperative; Pharmaceutical Chemistry; Quality of life; Resources; Role; Services; Speed; Strategic Planning; United States National Institutes of Health; Validation; assay development; base; chronic musculoskeletal pain; clinical pain; design; drug development; experimental study; improved; in vitro Assay; lead optimization; novel; pre-clinical; programs; small molecule

This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management. 1. Bioactivity Assay Bioactivity Assay consultants may be required to evaluate bioactivity assays and recommend strategies and experiments to optimize and/or validate the assays for use in a medicinal chemistry campaign. Bioactivity Assay consultants may be asked to assist in the establishment of milestones related to assay optimization or validation. The NIH may seek guidance from consultants on the design and interpretation of commonly used in vitro assays, such as biochemical and cell-based assays. Specific consulting responsibilities will depend on the expertise of the individual consultant and the needs of individual projects. Assay-related consultation services may be required on an ad hoc basis or on LDTs. The role of the Bioactivity Assay consultant may include but is not limited to the following responsibilities and tasks: • In partnership with other consultants, contractors, and NIH staff, advise, strategically plan, and manage programs to facilitate lead optimization, INDenabling studies, and clinical studies. • Serve as a resource to LDT for assay requirements and logistics to conduct drug development activities for small molecule compounds from the preclinical stage through to the initial clinical stage • Serve as the assay expert in order to identify potential developmental challenges and suggest strategies to address these challenges. • Collaborate on design of investigative studies in support of development compounds. This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management. It’s part of the program that establishes novel treatment options for a variety of pain conditions to improve quality of life and reduce opioid dependency. The program studies a broad range of pain conditions, including chronic overlapping pain conditions, chronic musculoskeletal pain, perioperative pain, and knee osteoarthritis.

这项研究是NIH的一部分，有助于长期（HEL）倡议结束成瘾，以加快科学解决方案，以了解疼痛的基础并增强临床疼痛管理。 1。生物活性测定 生物活性测定顾问可能需要评估生物活性分析和 推荐的策略和实验，以优化和/或验证用于在 药物化学运动。可以要求生物活性测定顾问协助 建立与测定优化或验证有关的里程碑。 NIH五月 向顾问寻求有关常用中使用的设计和解释的指导 体外测定，例如生化和基于细胞的测定。具体咨询 责任将取决于个人顾问的专业知识和 个别项目。可能需要在临时咨询服务 基础或LDT。 生物活性测定顾问的作用可能包括但不限于 以下责任和任务： •与其他顾问，承包商和NIH员工合作，建议， 策略性地计划并管理计划，以促进铅优化，垂直研究和临床研究。 •作为LDT的资源，以进行测定要求和物流进行药物 临床前阶段的小分子化合物的开发活动 到初始临床阶段 •充当测定专家，以确定潜在的发展挑战 并提出解决这些挑战的策略。 •在调查研究设计方面协作以支持发展 化合物。 这项研究是NIH的一部分，有助于长期（HEL）倡议结束成瘾，以加快科学解决方案，以了解疼痛的基础并增强临床疼痛管理。该计划的一部分为各种疼痛条件建立了新颖的治疗选择，以改善生活质量并减少阿片类药物的依赖性。该计划研究广泛的疼痛状况，包括慢性重叠疼痛状况，慢性肌肉骨骼疼痛，围手术期疼痛和膝关节骨关节炎。